Lv5
930 积分 2024-04-17 加入
An Innovative Approach to Optimize First‐In‐Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T‐Cell Engagers: Experience from A Solid Tumor Bispecific T‐Cell Engager
2个月前
已完结
Reimagining the Framework Supporting the Static Analysis of Transporter Drug Interaction Risk; Integrated Use of Biomarkers to Generate Pan‐Transporter Inhibition Signatures
2个月前
已完结
Exploratory food effect assessment in patients in early clinical development of oncology drugs
2个月前
已完结
Towards Rational Cancer Therapeutics: Optimizing Dosing, Delivery, Scheduling, and Combinations
2个月前
已完结
Pharmacometrics Golems: Exposure‐Response Models in Oncology
2个月前
已完结
Exploratory food effect assessment in patients in early clinical development of oncology drugs
2个月前
已完结
Utilization of OATP1B Biomarker Coproporphyrin‐I to Guide Drug–Drug Interaction Risk Assessment: Evaluation by the Pharmaceutical Industry
2个月前
已完结
Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR‐T and TCR‐T Cell Therapies: An Industry Perspective
2个月前
已完结
Development of Therapeutic Proteins for a New Subcutaneous Route of Administration After the Establishment of Intravenous Dosages: A Systematic Review
2个月前
已完结
Strategies and Recommendations for Using a Data‐Driven and Risk‐Based Approach in the Selection of First‐in‐Human Starting Dose: An International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Assessment
2个月前
已完结
皖公网安备34019202002308
